Early Access — free while we kick the tires
EdgarHawk

Cittadine Andrew

Chief Operating Officer

Officer
2 filings analyzed · 1 company · Latest 2024-06-21

Never miss a filing from Cittadine Andrew

Watch this insider and we'll alert you the moment they file — at any company.

Companies

Company Buys Sells Direction
Monopar Therapeutics MNPR 2 0 Net buying

Activity

June 2024
2024-06-21 Monopar Therapeutics MNPR
medium
Buy
32,508 shares
$25,574
Significance 5/10

COO Cittadine Andrew purchased 32,508 shares in 2 transactions at $0.79–$0.86, raising stake to 186,132 shares (+21.2%)

Cittadine Andrew, Chief Operating Officer, executed two separate purchases totaling 32,508 shares for $25,573.85 on June 18 and June 20, 2024, at prices between $0.74 and $0.86. This increased his holdings by 21.2%, from 153,624 to 186,132 shares. The company is currently unprofitable, reporting net income of $-1,641,226.00 over its most recent period and $0.00 in revenue in the latest quarter. The buys occurred within a narrow price band and were part of a cluster of five purchases by this insider at MNPR within the prior two weeks (June 3–17), though the timing outcomes of those earlier trades are not yet measurable. Current trading context shows the stock at $3.45, +12.3% over 30 days but -48.9% from its 52-week high of $6.75.

2024-06-17 Monopar Therapeutics MNPR
medium
Buy
36,000 shares
$32,894
Significance 6/10

COO Cittadine Andrew bought 36,000 shares at blended avg $0.91 (2024-06-13 through 2024-06-17) in unprofitable MNPR

Cittadine Andrew, Chief Operating Officer, executed 3 purchases totaling 36,000 shares for $32,894.40, raising his holdings from 117,624 to 153,624 shares (+30.6%). The buys span 2024-06-13 through 2024-06-17 at prices ranging from $0.90 to $0.93, just below Monopar's current price of $4.30 and well below the 52-week high of $6.75. Notably, the insider bought in quick succession across 5 separate transactions at MNPR within the prior two weeks (2024-05-29 through 2024-06-13), signaling sustained accumulation activity. The underlying company is unprofitable, with a negative net income of $-1,641,226.00 over its most recent full fiscal year and zero revenue in the latest quarter, limiting fundamental support for the stock price recovery that has occurred since these purchases.

Related insiders